Concerto Biosciences (LS ’21) has raised $23M in Series A funding to advance its first microbial product “Ensemble No.2”, designed to rehabilitate the skin microbiome, and its discovery platform kChip.
Concerto Biosciences (LS ’21) has raised $23M in Series A funding to advance its first microbial product “Ensemble No.2”, designed to rehabilitate the skin microbiome, and its discovery platform kChip.
